mavacamten


( Last Updated : September 28, 2022)
Generic Name:
mavacamten
Project Status:
Received
Therapeutic Area:
Obstructive hypertrophic cardiomyopathy
Manufacturer:
Bristol Myers Squibb
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0755-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult patients, aligned with the pivotal phase 3 EXPLORER-HCM patient population.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones

Call for patient/clinician input open24-Aug-22
Call for patient/clinician input closed17-Oct-22
Submission received22-Sep-22
Submission accepted